HER2 activating mutations are targets for colorectal cancer treatment

Cancer Discovery

Volumn 5, Issue 8, 2015, Pages 832-841

  Kavuri, Shyam M ^a,g   Jain, Naveen ^a   Galimi, Francesco ^b,c   Cottino, Francesca ^c   Leto, Simonetta M ^b,c   Migliardi, Giorgia ^b,c   Searleman, Adam C ^a   Shen, Wei ^a   Monsey, John ^a   Trusolino, Livio ^b,c   Jacobs, Samuel A ^d   Bertotti, Andrea ^b,c,e   Bose, Ron ^a,f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

^d NSABP Foundation Inc   (United States)

^e NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^f USA   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; NERATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTIBODY RESPONSE; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IC50; IN VITRO GENE TRANSFER; PROTEIN PHOSPHORYLATION; QUANTITATIVE ASSAY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; EPITHELIUM CELL; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUCOSA; MUTATION; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; HUMANS; MOLECULAR TARGETED THERAPY; MUCOUS MEMBRANE; MUTATION; QUINAZOLINES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939181687     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1211     Document Type: Article

References (38)

1. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333–9
2. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113–20
3. The Cancer Genome Atlas Consortium. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–7
4. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508–23
5. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFRdirected therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86
6. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3: 224–37
7. Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A 2012; 109: 14476–81
8. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25–38
9. ClinicalTrials.gov [homepage on the Internet]. Neratinib in metastatic HER2 non-amplified but HER2 mutant breast cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01670877. Access date Sept. 28, 2014
10. ClinicalTrials.gov [homepage on the Internet]. An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification. Available from: http://clinicaltrials.gov/ct2/show/NCT01953926. Access date Oct. 2, 2014
11. Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014; 32: 68–75
12. Besse B, Soria J-C, Yao B, Kris M, Chao B, Cortot A, et al. Neratinib (N) with or without temsirolimus (TEM) in patients (pts) with nonsmall cell lung cancer (NSCLC) carrying HER2 somatic mutations: An international randomized phase II study. Annals of Oncology 2014; 25: v1–v41; abstract LBA39 PR.
13. Chong CR, Janne PA. The quest to overcome resistance to EGFRtargeted therapies in cancer. Nat Med 2013; 19: 1389–400
14. Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014; 15: 454
15. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500
16. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401–4
17. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945–50
18. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: a metaanalysis of colorectal cancer survival data. Eur J Cancer 2010; 46: 2788–98
19. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer . J Clin Oncol 2010; 28: 3219–26
20. D’Abaco GM, Whitehead RH, Burgess AW. Synergy between Apc min and an activated ras mutation is sufficient to induce colon carcinomas . Mol Cell Biol 1996; 16: 884–91
21. Whitehead RH, VanEeden PE, Noble MD, Ataliotis P, Jat PS. Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc Natl Acad Sci U S A 1993; 90: 587–91
22. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532–6
23. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013; 2: e71
24. Moretti S, De Falco V, Tamburrino A, Barbi F, Tavano M, Avenia N, et al. Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. Biochim Biophys Acta 2009; 1793: 1634–45
25. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3: 658–73
26. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60–70
27. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011; 39: e118
28. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 2012; 40: W452–7
29. The Cancer Genome Atlas cBio Portal search performed August 30, 2104. Available from: http://www.cbioportal.org/public-portal/.
30. ClinicalTrials.gov [homepage on the Internet]. An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification. Available from: http://clinicaltrials.gov/ct2/ show/NCT01953926. Access date May 15, 2015
31. Kloth M, Ruesseler V, Engel C, Koenig K, Peifer M, Mariotti E, et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan- HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut 2015 Apr 28. [Epub ahead of print].
32. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109–19
33. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124–30
34. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–65
35. Kavuri SM, Geserick P, Berg D, Dimitrova DP, Feoktistova M, Siegmund D, et al. Cellular FLICE-inhibitory Protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex. J Biol Chem 2011; 286: 16631–46
36. Hadfield JD. MCMC methods for multi-response generalized linear mixed models: the MCMCglmm R package. J Stat Software 2010; 33: 1–22
37. Monsey J, Shen W, Schlesinger P, Bose R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem 2010; 285: 7035–44
38. Baralis E, Bertotti A, Fiori A, Grand A. LAS: a software platform to support oncological data management. J Med Syst 2012; 36: S81–90.